EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

BACKGROUND: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, H, Ballman, K, Vassilakopoulou, M, Dueck, A C, Reinholz, M M, Tenner, K, Gralow, J, Hudis, C, Davidson, N E, Fountzilas, G, McCullough, A E, Chen, B, Psyrri, A, Rimm, D L, Perez, E A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453859/
https://www.ncbi.nlm.nih.gov/pubmed/25117817
http://dx.doi.org/10.1038/bjc.2014.442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453859/
https://www.ncbi.nlm.nih.gov/pubmed/25117817
http://dx.doi.org/10.1038/bjc.2014.442

Ejemplares similares